|
Re: Resverlogix (RVX) Reports Fiscal Year 2017 Results
|
5
|
Resverlogix Corp.
|
Aug 15, 2017 06:26PM
|
|
Re: Resverlogix (RVX) Reports Fiscal Year 2017 Results
|
1
|
Resverlogix Corp.
|
Aug 16, 2017 10:58AM
|
|
Re: RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC LICENSING AGREEMENT
|
2
|
Resverlogix Corp.
|
Jan 09, 2018 06:31PM
|
|
Re: Resverlogix and Zenith Special Meetings
|
5
|
Resverlogix Corp.
|
Jul 01, 2015 10:36AM
|
|
Re: Resverlogix and Zenith Special Meetings
|
4
|
Resverlogix Corp.
|
Jul 01, 2015 11:42AM
|
|
Re: Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
|
5
|
Resverlogix Corp.
|
Aug 30, 2023 08:05PM
|
|
Re: Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
|
4
|
Resverlogix Corp.
|
Sep 08, 2021 10:58AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
3
|
Resverlogix Corp.
|
Dec 22, 2020 01:32PM
|
|
Re: Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
|
3
|
Resverlogix Corp.
|
Jun 18, 2018 08:34PM
|
|
Re: Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
|
2
|
Resverlogix Corp.
|
Jun 15, 2018 02:20PM
|
|
Re: Resverlogix announces HEPALINK debenture $6mill
|
4
|
Resverlogix Corp.
|
May 05, 2021 11:07AM
|
|
Re: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
|
3
|
Resverlogix Corp.
|
Jun 06, 2017 03:37PM
|
|
Re: Resverlogix Announces Lifting by TSX of Review
|
2
|
Resverlogix Corp.
|
May 11, 2018 03:48PM
|
|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
6
|
Resverlogix Corp.
|
Jun 13, 2023 09:08AM
|
|
Re: Resverlogix Announces One-Year Extension of Debenture
|
12
|
Resverlogix Corp.
|
Apr 20, 2022 11:51AM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
5
|
Resverlogix Corp.
|
Mar 31, 2020 05:52PM
|
|
Re: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
1
|
Resverlogix Corp.
|
Sep 30, 2019 04:34PM
|
|
Re: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
1
|
Resverlogix Corp.
|
Sep 30, 2019 09:05AM
|
|
Re: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
2
|
Resverlogix Corp.
|
Sep 30, 2019 09:57AM
|
|
Re: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
2
|
Resverlogix Corp.
|
Sep 30, 2019 10:31AM
|
